原料药 API

A core endocrine therapy for prostate cancer requiring continuous long-term dosing, ensuring stable annual API demand and well suited to long-term FSO supply arrangements.

A foundational agent in myelofibrosis with continued dermatology indication expansion; long-marketed with rigid, predictable demand, a low-volatility steady product.

Addresses high-unmet need in post-transplant GVHD with a clear mechanism and limited competition, well suited to registration partnerships with transplant centers.

A TGF-beta pathway inhibitor valuable both as an immuno-oncology combination component and in fibrosis, a dual-track development asset.

A China-originated ALK inhibitor with globally competitive efficacy and safety, a mature asset for domestic innovative-drug export and licensing.

An ATR inhibitor targeting the DNA-damage-repair pathway, a hot combination strategy with chemo-radiotherapy and PARP inhibitors, strong pipeline extensibility.

A second-generation XPO1 inhibitor with improved tolerability over the first generation, offering a clear substitution opportunity in elderly AML/MDS.

An SHP2 inhibitor confronting KRAS/EGFR resistance, a core combination partner with KRAS inhibitors and EGFR antibodies.

The mTOR pathway is a core resistance mechanism in breast and gynecologic cancers; combination regimens with endocrine therapy continue to advance.

An oral pan-AKT inhibitor explored in both hematologic and solid tumors, a common targeted candidate within diagnosis-to-treatment integrated pathways.